GLP-1 Medicines: The Regulatory Picture for UK Pharmacies and Clinics
GLP-1 medicines have transformed the weight-management market. Estimates suggest close to two million adults in Britain are now using weight-loss medication, and an oral GLP-1 tablet was approved by the MHRA for the first time in 2026. For providers, the regulatory picture has become just as important as the clinical one.
Advertising rules
UK law prohibits advertising prescription-only medicines to the public. The MHRA regularly publishes lists of online providers that have amended their websites after complaints, including references to GLP-1s or weight-loss injections that were judged likely to promote a prescription-only medicine. Providers can promote their clinical service, but not the medicine itself.
Safety updates
In early 2026, the MHRA strengthened its warnings for GLP-1 medicines on the rare but serious risk of acute pancreatitis, and it has updated its public guidance on safe use, including switching between products.
Tougher scrutiny of online prescribing
The General Pharmaceutical Council has published guidance that online pharmacies must follow when supplying weight-loss medicines, and its 2026 inspection analysis highlighted unsafe practice at some providers, such as prescribing to patients who did not meet eligibility criteria.
What this means for providers
Keep your marketing focused on the consultation and clinical care, not the product.
Make sure prescribing decisions are based on verified information.
Source stock only from licensed wholesalers with full traceability.
Acorn Pharmaceuticals supplies licensed pharmacies and clinics only, and we are happy to talk through supply for regulated weight-management services.
Talk to Acorn Pharmaceuticals: email gb@acornpharmaceuticals.co.uk or message us on WhatsApp.
Comments